Böttner Antje, Keller Eberhard, Kratzsch Jürgen, Stobbe Heike, Weigel Johannes F W, Keller Alexandra, Hirsch Wolfgang, Kiess Wieland, Blum Werner F, Pfäffle Roland W
University Hospital for Children and Adolescents, University of Leipzig, Oststrasse 21-25, 04317 Leipzig, Germany.
J Clin Endocrinol Metab. 2004 Oct;89(10):5256-65. doi: 10.1210/jc.2004-0661.
Mutations in the PROP1 gene are the most frequent genetic defects in patients with combined pituitary hormone insufficiency. However, controversy exists about the timing and extent of pituitary insufficiency, and it remains unclear whether adrenal failure is a typical feature of this condition. We performed a retrospective longitudinal analysis of nine patients with PROP1 mutations who were under medical supervision at our clinic for 15.7 +/- 3.4 yr. All patients initially presented with growth failure (height sd score, -3.7 +/- 0.3) at a mean age of 4.9 +/- 0.8 yr. They were first diagnosed with GH and TSH deficiency, and replacement therapy was instituted at 6.1 +/- 1.1 and 6.8 +/- 1.2 yr, respectively. All seven patients who reached pubertal age required sex hormone substitution at 15.0 +/- 0.7 yr. Repeated functional testing of the anterior pituitary axes revealed a progressive decline with age in peak levels of GH, TSH, prolactin, and LH/FSH. All patients developed at least partial adrenal insufficiency, with a gradual decline of the function of the pituitary adrenal axis and eventually required substitution with hydrocortisone at a mean age of 18.4 +/- 3.5 yr. It is concluded that anterior pituitary function in patients with PROP1 mutations deteriorates progressively and includes adrenal insufficiency as a feature of this condition, which has important clinical relevance in childhood and adolescence.
PROP1基因的突变是联合垂体激素缺乏症患者中最常见的遗传缺陷。然而,关于垂体功能不全的发生时间和程度存在争议,肾上腺功能衰竭是否为此病的典型特征仍不明确。我们对9例携带PROP1突变的患者进行了回顾性纵向分析,这些患者在我们诊所接受了15.7±3.4年的医学监测。所有患者最初均在平均年龄4.9±0.8岁时出现生长发育迟缓(身高标准差评分,-3.7±0.3)。他们最初被诊断为生长激素(GH)和促甲状腺激素(TSH)缺乏,并分别在6.1±1.1岁和6.8±1.2岁时开始进行替代治疗。所有7例进入青春期的患者均在15.0±0.7岁时需要进行性激素替代治疗。对垂体前叶轴进行的反复功能测试显示,GH、TSH、催乳素和促黄体生成素/促卵泡生成素(LH/FSH)的峰值水平随年龄增长而逐渐下降。所有患者均出现至少部分肾上腺功能不全,垂体-肾上腺轴功能逐渐减退,最终平均在18.4±3.5岁时需要氢化可的松替代治疗。结论是,携带PROP1突变患者的垂体前叶功能逐渐恶化,肾上腺功能不全是该病的一个特征,这在儿童期和青春期具有重要的临床意义。